<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052715</url>
  </required_header>
  <id_info>
    <org_study_id>NABTC-0105</org_study_id>
    <secondary_id>CDR0000258685</secondary_id>
    <secondary_id>NCI-2012-02506</secondary_id>
    <nct_id>NCT00052715</nct_id>
  </id_info>
  <brief_title>Biological Therapy and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
  <acronym>Poly-ICLC</acronym>
  <official_title>Phase II Trial Of Poly-ICLC For Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies such as poly-ICLC use different ways to stimulate the immune
      system and stop tumor cells from growing. Radiation therapy uses high-energy x-rays to damage
      tumor cells. Combining biological therapy with radiation therapy may kill more tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of combining poly-ICLC with radiation
      therapy in treating patients who have newly diagnosed glioblastoma multiforme.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the efficacy of poly ICLC and radiotherapy, in terms of total survival from
           date of diagnosis, in patients with newly diagnosed glioblastoma multiforme.

        -  Determine the safety and toxicity profile of this regimen in these patients.

        -  Determine the 12-month survival rate in patients treated with this regimen.

        -  Assess progression-free survival at 6 months and median progression-free survival from
           date of diagnosis of patients treated with this regimen.

        -  Assess response in patients treated with this regimen.

        -  Assess changes in neurological status in patients treated with this regimen.

      OUTLINE: This is a multicenter study.

      Within 1-4 weeks after surgery, patients receive poly ICLC intramuscularly 3 times weekly (on
      days 1, 3, and 5). Treatment continues in the absence of disease progression or unacceptable
      toxicity.

      One week after the initiation of poly ICLC, patients undergo external beam radiotherapy once
      daily 5 days a week for 6 weeks.

      Patients are followed monthly for 1 year and then every 3 months thereafter.

      PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study within 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    prematurely discontinued after results of the EORTC phase-3 study defined the SOC for newly
    diagnosed GMB pts as RT plus concomitant and adjuvant TMZ
  </why_stopped>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival in Pts With Newly Diagnosed GBM</measure>
    <time_frame>total survival from surgical diagnosis</time_frame>
    <description>Overall survival from surgical diagnosis in patients with Newly Diagnosed GBM</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Determine 6 Months Progression Free Survival</measure>
    <time_frame>6 months</time_frame>
    <description>Patients evaluated from date of diagnosis to the 6 month scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the 12-month Survival Rate</measure>
    <time_frame>1 year</time_frame>
    <description>12-month survival rate calculated from date of diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to Determine Grade 3 and 4 Toxicities Associated With Poly-ICLC in Newly Diagnosed Patients</measure>
    <time_frame>2 years</time_frame>
    <description>CTCAE 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Determine the Change in Neurological Status in Patients With Glioblastoma Treated With External Beam Radiotherapy and Poly-ICLC</measure>
    <time_frame>1 year</time_frame>
    <description>This was to be a descriptive measure per investigator, however, due to the reports of premature discontinuation of study agent in response to what turned out to be pseudo-progression, that outcome was not assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Determine Tumor Response</measure>
    <time_frame>2 years</time_frame>
    <description>Due to the reports of transient enlargement of contrast enhancing disease with subsequent shrinkage during Poly-ICLC treatment and the lack of central radiological review, the protocol defined criteria for radiological response could not be employed because of the risk of inconsistent results</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>poly-ICLC Newly diagnosed GBM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Poly-ICLC 20ug/kg 3 times a week (Monday-Wednesday-Friday) starting one week before Radiation Therapy
Intramuscular injection
Drug Poly-ICLC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>poly ICLC</intervention_name>
    <arm_group_label>poly-ICLC Newly diagnosed GBM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed intracranial glioblastoma multiforme (GBM) or gliosarcoma by
             biopsy or resection within the past 28 days

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Karnofsky 60-100%

        Life expectancy

          -  More than 8 weeks

        Hematopoietic

          -  WBC at least 3,000/mm^3

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 10 g/dL (transfusion allowed)

        Hepatic

          -  Bilirubin less than 2 times upper limit of normal (ULN)

          -  SGOT less than 2 times ULN

        Renal

          -  Creatinine less than 1.5 mg/dL

        Other

          -  No significant medical illness that cannot be controlled adequately with appropriate
             therapy or that would compromise tolerability of study therapy

          -  No other cancer (except nonmelanoma skin cancer or carcinoma in situ of the cervix)
             unless in complete remission and off all therapy for that disease for at least 3 years

          -  No active infection

          -  No disease that would obscure toxicity or dangerously alter drug metabolism

          -  No other serious concurrent medical illness

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior polifeprosan 20 with carmustine implant (Gliadel wafer)

          -  No concurrent chemotherapy

        Endocrine therapy

          -  Concurrent corticosteroids to treat symptoms or prevent complications are allowed

        Radiotherapy

          -  No prior radiotherapy to the brain

          -  No concurrent stereotactic radiosurgery

          -  No concurrent brachytherapy

        Surgery

          -  See Disease Characteristics

        Other

          -  No prior cytotoxic or noncytotoxic drug therapy for GBM

          -  No prior experimental drug therapy for GBM

          -  No other concurrent cytotoxic or noncytotoxic drug therapy for GBM

          -  Concurrent analgesics, antiepileptics, or other drugs to treat symptoms or prevent
             complications are allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Prados, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Butowski N, Chang SM, Junck L, DeAngelis LM, Abrey L, Fink K, Cloughesy T, Lamborn KR, Salazar AM, Prados MD. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neurooncol. 2009 Jan;91(2):175-82. doi: 10.1007/s11060-008-9693-3. Epub 2008 Sep 17.</citation>
    <PMID>18797818</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2003</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>January 26, 2017</results_first_submitted>
  <results_first_submitted_qc>January 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 16, 2017</results_first_posted>
  <last_update_submitted>January 26, 2017</last_update_submitted>
  <last_update_submitted_qc>January 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poly ICLC</mesh_term>
    <mesh_term>Poly I-C</mesh_term>
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients enrolled from 7/14/2003 through 12/19/2005. Patients recruited from outpatient clinic centers.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Poly-ICLC</title>
          <description>poly-ICLC given at dose of 20mcg/kg 3 times weeekly by intramusclular injection. days of administration were at least 2 days apart. Mon-Wed-fri
Poly-ICLC drug
poly ICLC</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>wrong histology</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Poly-ICLC</title>
          <description>poly-ICLC given at dose of 20mcg/kg 3 times weeekly by intramusclular injection. days of administration were at least 2 days apart. Mon-Wed-fri
Poly-ICLC drug
poly ICLC</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="26" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Status Scale</title>
          <description>Higher score better 100 normal no complaints/disease 90 capable normal activity few symptoms/disease 80 normal activity, some difficulty some symptoms/signs 70 caring for self not capable normal activity/work 60 requiring some help can take care of most personal requirements 50 requires help often requires frequent medical care 40 disabled requires special care/help 30 severely disabled hospital admission indicated but no risk of death 20 very ill urgently requiring admission requires supportive measures/treatment 10 moribund rapidly progressive fatal disease processes 0 death</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90" lower_limit="60" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histology Glioblastoma</title>
          <description>WHO Classification</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Extent of Resection</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Biopsy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subtotal resection</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Gross Total resection</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival in Pts With Newly Diagnosed GBM</title>
        <description>Overall survival from surgical diagnosis in patients with Newly Diagnosed GBM</description>
        <time_frame>total survival from surgical diagnosis</time_frame>
        <population>Four patents were censored for survival at 35, 114, 126, and 166 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Poly-ICLC Newly Diagnosed GBM</title>
            <description>Poly-ICLC 20ug/kg 3 times a week (Monday-Wednesday-Friday) starting one week before Radiation Therapy
Intramuscular injection
Drug Poly-ICLC
poly ICLC</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival in Pts With Newly Diagnosed GBM</title>
          <description>Overall survival from surgical diagnosis in patients with Newly Diagnosed GBM</description>
          <population>Four patents were censored for survival at 35, 114, 126, and 166 weeks</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="54.8" upper_limit="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine 6 Months Progression Free Survival</title>
        <description>Patients evaluated from date of diagnosis to the 6 month scan</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Poly-ICLC Newly Diagnosed GBM</title>
            <description>Poly-ICLC 20ug/kg 3 times a week (Monday-Wednesday-Friday) starting one week before Radiation Therapy
Intramuscular injection
Drug Poly-ICLC
poly ICLC</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine 6 Months Progression Free Survival</title>
          <description>Patients evaluated from date of diagnosis to the 6 month scan</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine the 12-month Survival Rate</title>
        <description>12-month survival rate calculated from date of diagnosis</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Poly-ICLC Newly Diagnosed GBM</title>
            <description>Poly-ICLC 20ug/kg 3 times a week (Monday-Wednesday-Friday) starting one week before Radiation Therapy
Intramuscular injection
Drug Poly-ICLC
poly ICLC</description>
          </group>
        </group_list>
        <measure>
          <title>Determine the 12-month Survival Rate</title>
          <description>12-month survival rate calculated from date of diagnosis</description>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>to Determine Grade 3 and 4 Toxicities Associated With Poly-ICLC in Newly Diagnosed Patients</title>
        <description>CTCAE 4</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Poly-ICLC Newly Diagnosed GBM</title>
            <description>Poly-ICLC 20ug/kg 3 times a week (Monday-Wednesday-Friday) starting one week before Radiation Therapy
Intramuscular injection
Drug Poly-ICLC
poly ICLC</description>
          </group>
        </group_list>
        <measure>
          <title>to Determine Grade 3 and 4 Toxicities Associated With Poly-ICLC in Newly Diagnosed Patients</title>
          <description>CTCAE 4</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever without infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rigor/Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine the Change in Neurological Status in Patients With Glioblastoma Treated With External Beam Radiotherapy and Poly-ICLC</title>
        <description>This was to be a descriptive measure per investigator, however, due to the reports of premature discontinuation of study agent in response to what turned out to be pseudo-progression, that outcome was not assessed.</description>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine Tumor Response</title>
        <description>Due to the reports of transient enlargement of contrast enhancing disease with subsequent shrinkage during Poly-ICLC treatment and the lack of central radiological review, the protocol defined criteria for radiological response could not be employed because of the risk of inconsistent results</description>
        <time_frame>2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Poly-ICLC</title>
          <description>poly-ICLC given at dose of 20mcg/kg 3 times weeekly by intramusclular injection. days of administration were at least 2 days apart. Mon-Wed-fri
Poly-ICLC drug
poly ICLC</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE 4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphocytopenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Granulocytopenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radiation recall reaction (dermatologic)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood Bilirubin Increase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain (Other)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Neuropathy Sensory</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Speech Impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>alopecia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hyperidrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Enrollment was prematurely discontinued after the results of the EORTC phase-3 study defined the standard of care for newly diagnosed glioblastoma patients as radiotherapy plus concomitant and adjuvant temozolomide</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michael Prados, MD</name_or_title>
      <organization>North American Brain Tumor Consortium</organization>
      <phone>410-955-8837</phone>
      <email>jfisher@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

